GENE vs. SRTS
Compare and contrast key facts about Genetic Technologies Limited (GENE) and Sensus Healthcare, Inc. (SRTS).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: GENE or SRTS.
Key characteristics
| GENE | SRTS | |
|---|---|---|
| YTD Return | 1.67% | 124.58% |
| 1Y Return | -48.63% | 83.39% |
| 3Y Return (Ann) | -48.77% | 17.88% |
| 5Y Return (Ann) | -35.81% | -0.37% |
| Sharpe Ratio | -0.76 | 1.02 |
| Daily Std Dev | 64.16% | 84.75% |
| Max Drawdown | -99.87% | -87.51% |
| Current Drawdown | -99.82% | -64.60% |
Fundamentals
| GENE | SRTS | |
|---|---|---|
| Market Cap | $10.50M | $86.72M |
| EPS | -$0.15 | $0.03 |
| PEG Ratio | 0.00 | 0.00 |
| Revenue (TTM) | $10.24M | $24.41M |
| Gross Profit (TTM) | $6.01M | $29.63M |
| EBITDA (TTM) | -$9.86M | -$107.00K |
Correlation
The correlation between GENE and SRTS is 0.08, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
GENE vs. SRTS - Performance Comparison
In the year-to-date period, GENE achieves a 1.67% return, which is significantly lower than SRTS's 124.58% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
GENE vs. SRTS - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Genetic Technologies Limited (GENE) and Sensus Healthcare, Inc. (SRTS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
GENE vs. SRTS - Dividend Comparison
Neither GENE nor SRTS has paid dividends to shareholders.
Drawdowns
GENE vs. SRTS - Drawdown Comparison
The maximum GENE drawdown since its inception was -99.87%, which is greater than SRTS's maximum drawdown of -87.51%. Use the drawdown chart below to compare losses from any high point for GENE and SRTS. For additional features, visit the drawdowns tool.
Volatility
GENE vs. SRTS - Volatility Comparison
The current volatility for Genetic Technologies Limited (GENE) is 30.56%, while Sensus Healthcare, Inc. (SRTS) has a volatility of 35.63%. This indicates that GENE experiences smaller price fluctuations and is considered to be less risky than SRTS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
GENE vs. SRTS - Financials Comparison
This section allows you to compare key financial metrics between Genetic Technologies Limited and Sensus Healthcare, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities